» Articles » PMID: 17386054

Idiosyncratic Adverse Reactions to Antiepileptic Drugs

Overview
Journal Epilepsia
Specialty Neurology
Date 2007 Mar 28
PMID 17386054
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Idiosyncratic drug reactions may be defined as adverse effects that cannot be explained by the known mechanisms of action of the offending agent, do not occur at any dose in most patients, and develop mostly unpredictably in susceptible individuals only. These reactions are generally thought to account for up to 10% of all adverse drug reactions, but their frequency may be higher depending on the definition adopted. Idiosyncratic reactions are a major source of concern because they encompass most life-threatening effects of antiepileptic drugs (AEDs), as well as many other reactions requiring discontinuation of treatment. Based on the underlying mechanisms, idiosyncratic reactions can be differentiated into (1) immune-mediated hypersensitivity reactions, which may range from benign skin rashes to serious conditions such as drug-related rash with eosinophilia and systemic symptoms; (2) reactions involving unusual nonimmune-mediated individual susceptibility, often related to abnormal production or defective detoxification of reactive cytotoxic metabolites (as in valproate-induced liver toxicity); and (3) off-target pharmacology, whereby a drug interacts directly with a system other than that for which it is intended, an example being some types of AED-induced dyskinesias. Although no AED is free from the potential of inducing idiosyncratic reactions, the magnitude of risk and the most common manifestations vary from one drug to another, a consideration that impacts on treatment choices. Serious consequences of idiosyncratic reactions can be minimized by knowledge of risk factors, avoidance of specific AEDs in subpopulations at risk, cautious dose titration, and careful monitoring of clinical response.

Citing Articles

Drug-Induced Liver Injury-Pharmacological Spectrum Among Children.

Maris B, Grama A, Pop T Int J Mol Sci. 2025; 26(5).

PMID: 40076629 PMC: 11901067. DOI: 10.3390/ijms26052006.


Mechanistic insight of curcumin: a potential pharmacological candidate for epilepsy.

Khatoon S, Kalam N Front Pharmacol. 2025; 15():1531288.

PMID: 39845785 PMC: 11752882. DOI: 10.3389/fphar.2024.1531288.


Cenobamate as an Early Adjunctive Treatment in Drug-Resistant Focal-Onset Seizures: An Observational Cohort Study.

Winter Y, Abou Dargham R, Patino Tobon S, Groppa S, Fuest S CNS Drugs. 2024; 38(9):733-742.

PMID: 39096467 PMC: 11316687. DOI: 10.1007/s40263-024-01109-9.


An In Vivo and In Silico Approach Reveals Possible Sodium Channel Nav1.2 Inhibitors from as a Novel Treatment for Epilepsy.

Ashraf A, Ahmed A, Juffer A, Carter W Brain Sci. 2024; 14(6).

PMID: 38928545 PMC: 11202011. DOI: 10.3390/brainsci14060545.


Initiation of Antiseizure Medications by US Board-Certified Neurologists After a First Unprovoked Seizure Based on EEG Findings.

Lemus H, Villamar M, Roth J, Tobochnik S Neurol Clin Pract. 2024; 14(1):e200249.

PMID: 38204587 PMC: 10775163. DOI: 10.1212/CPJ.0000000000200249.